News Releases

Date	Title and Summary	View
Apr 26, 2018	Johnson & Johnson Announces Dividend Increase of 7.1% Johnson & Johnson Announces Dividend Increase of 7.1% NEW BRUNSWICK, N.J., April 26, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate, from $0.84 per share to $0.90 per share. The increase was
Apr 24, 2018	Johnson & Johnson to Participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference NEW BRUNSWICK, N.J. , April 24, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Deutsche Bank 43 rd Annual Health Care Conference on Wednesday, May 9 th , at The InterContinental Boston . Mathai Mammen, MD, Ph.D., Global Head, Research & Development, Janssen
Apr 17, 2018	Johnson & Johnson Reports 2018 First-Quarter Results: 2018 First-Quarter Sales of $20.0 Billion Increased 12.6% versus 2017 2018 First-Quarter EPS was $1.60 2018 Adjusted First-Quarter EPS of $2.06 increased 12.6%* Sales Momentum Continued in the First Quarter Strong Adjusted EPS Growth of 12.6%* Company Increased Sales and Reaffirms EPS Guidance
Apr 16, 2018	Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases
Apr 12, 2018	INVOKANA® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease New analysis further supports the potential renal protective effects of INVOKANA ® Austin, TX, April 12, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced an additional analysis from the landmark CANVAS Program showing INVOKANA ® (canagliflozin) improved renal
Apr 11, 2018	Johnson & Johnson Vision Announces Revolutionary Contact Lens Innovation with ACUVUE OASYS® with Transitions® Light Intelligent Technology™ Developed in strategic partnership with Transitions Optical, this one-of-a-kind contact lens corrects vision and adapts to changing light conditions
Mar 20, 2018	Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson Joseph Wolk Promoted to Executive Vice President, Chief Financial Officer
Mar 20, 2018	Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
Mar 16, 2018	Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc. NEW BRUNSWICK, N.J. , March 16, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion , subject to customary adjustments.
Mar 15, 2018	Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer